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ApolipoproteinE (APOE) is themajor risk factor for sporadicAlzheimer’sdisease.Amongother functions,APOE isproposed to sequester
neurotoxic amyloid- (A) peptides in the brain, delivering them to cellular catabolism via neuronal APOE receptors. Still, the receptors
involved in this process remain controversial. Here, we identified the pro-neurotrophin receptor sortilin asmajor endocytic pathway for
clearance of APOE/A complexes in neurons. Sortilin binds APOE with high affinity. Lack of receptor expression in mice results in
accumulation of APOE and of A in the brain and in aggravated plaque burden. Also, primary neurons lacking sortilin exhibit signifi-
cantly impaired uptake of APOE/A complexes despite proper expression of other APOE receptors. Despite higher than normal brain
APOE levels, sortilin-deficient animals display anomalies in brain lipid metabolism (e.g., accumulation of sulfatides) seen in APOE-
deficient mice, indicating functional deficiency in cellular APOE uptake pathways. Together, our findings identified sortilin as an essential
neuronal pathway for APOE-containing lipoproteins in vivo and suggest an intriguing link between A catabolism and pro-neurotrophin
signaling converging on this receptor.
Introduction
Sortilin is a member of the family of vacuolar protein sorting 10
protein (VPS10P) domain receptors, a group of type-1 mem-
brane proteins with important roles in regulation of neuronal
viability and function (Nykjaer and Willnow, 2012). Sortilin is
expressed in neurons of the CNS and PNS but also in extra-
neuronal tissues, including liver and fat (Petersen et al., 1997;
Morris et al., 1998; Sarret et al., 2003; Kjolby et al., 2010). Most
notably, sortilin is recognized for its activity as a receptor for
pro-nerve growth factor (proNGF) and pro-brain-derived neu-
rotrophic factor required for induction of neuronal cell death by
these proapoptotic molecules (Nykjaer et al., 2004; Teng et al.,
2005). Sortilin-dependent induction of cell death has been doc-
umented during development and aging, as well as in acute in-
sults to the nervous system (Jansen et al., 2007). Surprisingly,
recent studies uncovered a distinct function for this receptor in
hepatocytes in which it interacts with apolipoprotein (APO)
B100 to control assembly and hepatic release of lipoproteins into
the circulation (Kjolby et al., 2010; Musunuru et al., 2010). This
observation suggested a mechanistic link between lipoprotein
metabolism and regulation of neuronal viability that converges
on this receptor pathway.
With respect to neuronal viability, the relevance of sortilin as a
death receptor in acute neuronal injury (e.g., spinal cord injury)
iswell appreciated (Jansen et al., 2007).However, its contribution
to chronic neurodegenerative processes as in Alzheimer’s disease
(AD) remains less clear. Such a role had been contemplated based
on the fact that proNGF concentrations are increased in the brain
of AD patients (Fahnestock et al., 2001). In support of this hy-
pothesis, sortilin levels in brain specimens from patients with AD
or with mild cognitive impairment were positively correlated
with the severity of neuropathology, suggesting increased
proNGF signaling through sortilin as an underlying cause of neu-
rodegeneration (Mufson et al., 2010). As an alternative hypothe-
sis, sortilin was reported to regulate trafficking of BACE1 (-site
APP-cleaving enzyme), and the enzyme responsible for initiat-
ing amyloidogenic cleavage of the amyloid precursor protein
(APP), the main etiologic agent in AD (Finan et al., 2011). The
latter model is in line with functions of related VPS10P domain
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receptors SORLA (sorting protein-related receptor) and SORCS1
(sortilin-related receptor CNS expressed) that modulate amy-
loidogenic processing through control of intracellular sorting
of APP (Andersen et al., 2005; Schmidt et al., 2007; Lane et al.,
2010).
Although intriguing, studies on the role of sortilin in AD have
so far solely relied on in vitro studies. Now, we applied mouse
models with targeted Sort1 gene disruption to query the relevance
of this receptor pathway for AD-related processes in vivo. Mice
lacking sortilin exhibit increased brain levels of amyloid- (A)
peptides and show aggravated plaque burden, substantiating the
significance of this receptor for amyloidogenic processes. How-
ever, contrary to previous hypotheses, our data revealed that
sortilin does not affect APP processing in cells or in vivo. Rather,
it acts as an apolipoprotein E (APOE) receptor in neurons, con-
stituting a major endocytic pathway for catabolism of A bound
to this APO in the brain.
Materials andMethods
Materials. Recombinant human APOE4 (Calbiochem, MBL), APOE3
(Alpha Diagnostics, Sigma), and HiLyte Fluor 488-labeled -amyloid
(1–40) (Anaspec) were obtained commercially. The pro-domain of mu-
rine NGF (amino acids E19 to R121) was expressed in Escherichia coli as
a glutathione S-transferase (GST) fusion protein and purified on gluta-
thione–agarose beads. APOE-deficient high-density lipoprotein (HDL)
was isolated from plasma of healthy donors as described previously (Rel-
lin et al., 2008). APOE-conditioned media were produced by transient
transfection of HEK293 cells with expression constructs encoding hu-
man APOE2, APOE3, or APOE4 (Chen et al., 2010) and collected in
DMEM without fetal calf serum for 48 h. Proteoliposomes containing
APOE2, APOE3, and APOE4 were prepared according to published pro-
tocols (Heeren et al., 1999).
Mouse and cell models. PDAPP (mice ex-
pressing human APP V717F variant under
control of the human platelet derived growth
factor -chain gene promoter) (Games et al.,
1995), Sorl1/ (Andersen et al., 2005),
Apoe/ (Plump et al., 1992), 5xFAD (Oakley
et al., 2006), and Sort1/ (Jansen et al., 2007)
lines of mice have been described previously.
Mice carrying a loxP-modified Lrp1 allele
(Rohlmann et al., 1996) were bred to animals
transgenic for Cre recombinase under control
of the neuron-specific enolase promoter (Nse–
creCK1) (Kwon et al., 2006). Experimental pro-
cedures involving animals were performed
following approval by local authorities. Pri-
mary hippocampal neurons were prepared
from newborn mice (P1–P2) and cultured for
7–10 d in Neurobasal-A medium (Invitrogen)
supplemented with B27 (Invitrogen) and Glu-
taMAX (Invitrogen). Primary cultures of cor-
tical astrocytes were prepared from cortices of
P0 mice by digestion in trypsin/EDTA solu-
tion. Tissues were triturated in DMEM with
10% FCS and DNase and seeded in poly-L-
lysine-coated T75 flask in DMEM with 10%
FCS and primocin.
Metabolic labeling of primary astrocyte cul-
tures. Astrocyte cultures in six-well 36-mm
plate format were metabolically labeled using
[ 35S]Met/[ 35S]Cys in DMEM without Met/
Cys supplemented with 2% dialyzed FCS and
Brefeldin A (10 g/ml) for 4 h at 37°C. Cells
were washed twice in DMEM before addition
of DMEM plus 2% FCS and incubation at
37°C. At indicated time points, conditioned
media and cell lysate were harvested and sub-
ject to immunoprecipitation with 1 g of anti-APOE IgG (Calbiochem)
coupled to -bind beads. Precipitated proteins were visualized by SDS-
PAGE and autoradiography.
BIAcore. Surface plasmon resonance analysis was performed on a BIA-
core 2000 instrument (GE Healthcare) equipped with CM5 sensor chips
coupled with the recombinant extracellular domain of sortilin (0.046
pmol/mm2) as published previously (Nykjaer et al., 2004). Proteolipo-
somes, in the absence or presence of 20 M neurotensin (NT), were
diluted in 10mMHEPES, 150mMNaCl, 1.5 mM CaCl2, and 1mM EGTA,
pH 7.4 (running buffer) and injected at 5 pmol/min for 5 min, at 4°C.
Kinetic parameters were determined using the BIAevaluation 3.0 soft-
ware. The number of APOE isoforms bound per moles of immobilized
sortilin was estimated by dividing the ratio RUligand/massligand with
RUsortilin/masssortilin (in which RU is response units).
Quantitative RT-PCR. Real time RT-PCR was performed on cDNA re-
versely transcribed from total RNA using a 7900HTReal-Time PCR system
(AppliedBiosystems) (Rohe et al., 2009).Transcriptsweredeterminedusing
commercial Assay-on-Demand primer/probe sets (Applied Biosystems).
Each template was run in triplicates, and relative expression levels were cal-
culated by normalization to the internal control 2microglobulin.
Determination of APP processing and plaque burden. Intensities of im-
munoreactive bands of Western blot analyses were quantified by optical
densitometry using NIH ImageJ software (http://rsb.info.nih.gov/ij/).
A40/42 [soluble (s) fraction] as well as sAPP and sAPP levels in brain
extracts or cell media were analyzed using commercial ELISA kits (Me-
soscaleDiscovery) andBACE1 activity by BACE1 fluorescence resonance
energy transfer (FRET) assay kit (Invitrogen). For determination of
plaque burden, two to six hippocampal paraffin sections (5 m) from
5xFAD; Sort1/ (2 and 10 months) and 5xFAD; Sort1/ (2 and 10
months)micewere stainedwith 1%Thioflavin S (Sigma).Quantification
of density of thioflavin S staining was performed using NIH ImageJ
software in single optical images. Plaque density was related to the hip-
pocampal area and averaged for each animal studied.
Figure 1. Sortilin deficiency selectively increases A levels in the murine brain. A, B, Levels of murine APP protein (A; mAPP)
and AppmRNA (B) are unchanged in extracts of sortilin-deficient (Sort1/) comparedwith control (Sort1/) mouse brains as
shown by Western blotting and quantitative RT-PCR, respectively (n 4 per genotype for B). C, D, Cortical levels of human APP
protein (hAPP) are identicalwhen comparing Sort1/and Sort1/miceon thePDAPPbackgroundbyWesternblotting (C) and
densitometric scanningof replicate blots (D;n3per genotype).E, Levels of sAPP, sAPP, andA40weredeterminedby ELISA
in brain extracts of PDAPP wild-type mice (PDAPP/; Sort1/; white bars) or mice homozygous for the Sort1 null allele
(PDAPP/; Sort1/; black bars) (n 3–7 per group). F, G, A40 levels in hippocampus (Hip) and cortex (Ctx) of mice of the
indicated genotypes at 5months (F; n 3–5 per group) and 9months (G; n 8–10 per group) of age. Values aremean SEM.
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Uptake studies in established and primary cell cultures. For determina-
tion of APOE uptake, cells were incubated with supernatant from mock
transfectants or HEK293 cells transfected with human APOE expression
constructs. After 30 min incubation at 37°C, the ligand-containing me-
dium was removed, and cells were washed in PBS containing 500 U/ml
heparin and subjected to standard confocal immunofluorescence mi-
croscopy. For detection of surface binding, Triton X-100 was omitted
from the incubation buffers. To determine cellular uptake of A, human
recombinant APOE4 was associated with HDL in a ratio of 1:1 with
respect to HDL protein content (Rellin et al., 2008). HiLyte–A was
added to the lipidated APOE mixture and incubated at 37°C for 1 h to
allow complex formation. As a negative control, free HiLyte–A was
mixed with APOE-free HDL. Internalization of HiLyte–A was evalu-
ated by confocal immunofluorescence microscopy of cells treated with
10 g/ml (lipidated APOE) or 1 M HiLyte–A40 for 1 h at 37°C. For
quantification of uptake (see Fig. 10B), unbound A was removed by
dialysis in PBS for 4 h. A concentration in the dialyzed fraction was
measured by ELISA.
Lipid analyses. We modified the method described by Han et al.
(2003). Thus, frozen brain tissues were homogenized in a precooled
methanol/chloroform/water (5:2:1) mixture at a final ratio of 50 mg of
tissue per 1 ml of solvent. Samples were homogenized in a Precellys 24
homogenizer (Bertin Technologies) two times for 20 s at 5.500 Hz. Solid
debris were removed by centrifugation for 10min at 10,000 g, and 100
l of supernatant were dried under vacuum overnight. Dried samples
were resuspended in 1 ml of methanol containing 1 g/mlN-palmitoyl-
sulfatide (Matreya) as internal standard for the following analysis. For
mass spectrometric analysis, 5l of sample were injected at 20l/min by
an Agilent 1200UPLC system (Agilent Technologies) directly into a TSQ
Vantage mass spectrometer (Thermo Fisher Scientific) using a flow in-
jection analysis. Acquisition was performed in negative mode, scanning
Q3 quadrupole from 500–1050mass/charge. The spray voltage was set at
3000 V, sheath gas at 13 arbitrary units, capillary temperature at 260°C,
and S-Lens RF amplitude at 71 V. No gas was used in the collision cell.
Abundance values for N24:1 sulfatide were calculated as the ratio of their
intensities and the intensity of the internal standard. Intensities were
calculated by automatic integration byXcalibur software (ThermoFisher
Scientific) and were validated manually.
Statistical analyses of data. Results comparing two groups were ana-
lyzed by Student’s t test (see Figs. 3C, 14) or Mann–Whitney U test (all
others). To compare the means of more than two groups, we used one-
way (see Fig. 10C) or two-way (see Figs. 10B, 13B) ANOVA. F values and
degrees of freedom are stated in the respective figure legends. When
applicable, post hoc differences were compared using Bonferroni’s test.
All statistical analyses were performed using GraphPad Prism 5 software.
Results
Loss of sortilin increases brain A levels in mice
Mice with targeted disruption of Sort1 (the gene encoding sortilin)
have been generated by us previously (Jansen et al., 2007). Here, we
crossed Sort1/ animals with the PDAPP line of mice, an estab-
lished model of amyloidogenic processing carrying the human
APPV717F gene variant (Games et al., 1995). Loss of receptor expres-
sion did not alter total brain levels of endogenous murine (Fig.
1A,B) or human APP (Fig. 1C,D) in these mice compared with
controls.However, lackof sortilin resulted ina significant increase in
A40 levels in brain extracts ofPDAPP
/; Sort1/mice compared
with PDAPP/; Sort1/ controls (Fig. 1E). Intriguingly, the in-
crease in A40 was not paralleled by corresponding changes in the
levels of sAPP or sAPP fragments in affected animals (Fig. 1E). A
rise inA40 levels inPDAPP
/; Sort1/micewas seen both in the
hippocampus and in the cortex at 5months (Fig. 1F) and 9months
(Fig. 1G) of age. Unimpaired proteolytic activity in the sortilin-
deficient mouse brain was substantiated by Western blot anal-
ysis of C-terminal fragments C83 and C99, the products of -
and -secretases, respectively (Fig. 2A,B), and by determina-
tion of BACE1 activity using FRET assay (Castellano et al.,
2011) (Fig. 2C).
The effect of sortilin deficiency on amyloidogenic processingwas
confirmed in 5xFAD mice, another commonly used AD model
(Oakley et al., 2006). Thus, elevated levels of A40 were seen in
5xFADmice lacking sortilin (5xFAD;Sort1/) comparedwith con-
trol mice (5xFAD; Sort1/) at 2 months of age (Fig. 3A) and re-
sulted in an aggravated plaque burden as documented by thioflavin
S stainingof hippocampal sections (Fig. 3B,C). At 10months of age,
the aggressive plaque burden observable in the 5xFAD model
masked the consequencesof sortilindeficiencyonplaquedeposition
(Fig. 3B,C). This finding suggested an effect of receptor activity on
time of onset and early progression of amyloidosis. Together, quan-
titativeanalysesofAPPmetabolism invivodemonstratedan increase
in A concentrations in Sort1/ animals that accelerated onset of
senile plaques deposition. Because levels of soluble or membrane-
bound APP processing products or -secretase activity were not
altered in these mice, our data argued for a role of sortilin in catab-
olism of A peptides in the brain.
Loss of sortilin impairs neuronal catabolism of APOE
Several mechanisms have been shown to affect the half-life of A
peptides in brain parenchyma, including shunt into the circula-
tion or enzymatic breakdown in the extracellular space (for re-
view, see Kurz and Perneczky, 2011). The plasma levels of A40
Figure 2. Sortilin deficiency does not impact- and-secretase activities. A, B, Quantita-
tive analysis of C-terminal fragments (CTF) C99 and C83 in total brain extracts of Sort1/ and
Sort1/mice on the PDAPP background using Western blotting (A) and densitometric scan-
ning of replicate blots (B; n 7–11 per genotype). Detection of APP and tubulin served as
loading controls in A. C, Activity of BACE1 inmice of the indicate genotypes using FRET assay as
described in Materials and Methods (n 4 per group). RFU, Relative fluorescent unit.
360 • J. Neurosci., January 2, 2013 • 33(1):358–370 Carlo et al. • Sortilin Mediates APOE-Dependent Catabolism of A
were identical in PDAPP/; Sort1/
and control animals (Fig. 4A). Also, the
levels of the A-degrading enzymes CD10
(neprilysin) (Iwata et al., 2001) and insu-
lin degrading enzyme (Farris et al., 2003)
were not altered in the brain of receptor-
deficient mice as shown by Western blot
analyses (Fig. 4B). Thus, neither of the
two mechanisms seemed likely responsi-
ble for the increase in A levels in
Sort1/mice. Conceivably, brain pathol-
ogy as a consequence of altered (pro)-
neurotrophin signaling may secondarily
increase A levels in sortilin-deficient
mice. However, no signs of overt neuro-
pathology were observable in histological
brain sections from receptor null mice
stained with thionine or antibodies di-
rected against GFAP or NeuN, markers of
glia cells and neurons, respectively (Fig.
5). Also, immunostaining for F4/80 failed
to reveal any signs of reactive microglia in
this mouse line (data not shown).
Another pathway implicated in brain
turnover of A is clearance by APOE re-
ceptors when the peptide is bound to
APOE (Koistinaho et al., 2004; Morikawa
et al., 2005; Jiang et al., 2008). Interest-
ingly, a twofold increase in the concentra-
tion of APOE in hippocampus and cortex
of sortilin null mice was evident when de-
termining protein levels by Western blot
(Fig. 6A,B). Elevated levels of APOE were
not attributable to an increased rate of
transcription as demonstrated by quanti-
tative RT-PCR of Apoe transcripts in hip-
pocampal and cortical tissues of the
respective animals (Fig. 6C). Also, the rate
of secretion of APOE from astrocytes, the
main source of this APO in the brain, was
not affected by the absence of the receptor
as shown by metabolic labeling experi-
ments in primary astrocyte cultures (Fig.
7). Thus, our data argued for impaired
cellular uptake of APOE as the cause of A
accumulation and deposition in the brain
of sortilin-deficient mice.
Sortilin acts as endocytic receptor
for APOE
The ability of sortilin to bind APOB100
has been reported previously (Kjolby et
al., 2010; Musunuru et al., 2010). How-
ever, a possible function as receptor for
Figure 3. Sortilin deficiency increases plaque burden in the brain. A, Levels of A40 were determined by ELISA in extracts of
hippocampus (Hip) and cortex (Ctx) of 5xFAD mice either wild-type (5xFAD; Sort1/) or homozygous for the Sort1 null allele
(5xFAD; Sort1/) at 2months of age (n 5–6 per group).B, Thioflavin S staining of sagittal sections through the brain of three
to four individual mice at 2 and 10months of age. Deposition of plaques (arrowheads) in the subiculum is seen in 2-month-old
4
5xFAD mice lacking sortilin (5xFAD; Sort1/) but not in the
age- and gender-matched controls (5xFAD; Sort1/). At 10
months of age, a massive plaque burden is seen in both geno-
types. Scalebar, 150m.C, Quantificationofplaqueburden in
individual mice of the indicated age and genotype based on
thioflavin S staining as exemplified inB (n2–6 sections per
animal). *p 0.05.
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APOE has not been documented so far. Thus, we applied surface
plasmon resonance analysis to test the ability of sortilin to inter-
act with the latter APO. As test ligands, we used proteoliposomes
enriched with recombinant human APOE2, APOE3, and APOE4
(Heeren et al., 1999). As shown in Figure 8A–C, the extracellular
domain of sortilin bound all three APOE isoforms (Kd 117 nM
for APOE2; Kd  44 nM for APOE3; Kd  114 nM for APOE4).
Binding was significantly reduced by NT, a neuropeptide that
binds to the VPS10P domain and blocks interaction with ligands
that target this receptor domain (Mazella et al., 1998; Quistgaard
et al., 2009). In contrast, poor binding to the sortilin ectodomain
was seen for isolated A40 (Fig. 8D; Kd 0.8 M).
To further substantiate a role for sortilin asAPOE receptor, we
tested its ability to mediate endocytic uptake of this APO into
cells. To do so, we generated a Chinese hamster ovary (CHO) cell
line that stably overexpressesmurine sortilin (CHO–mSort). The
receptor mainly localized to intracellular compartments in
CHO–mSort cells, in line withwhat has been observed previously
in other cell types (Fig. 9A) (Nielsen et al., 2001). Despite a pre-
dominant intracellular localization, sortilin efficiently internal-
ized ligands as shown for GST–pro, a surrogate ligand composed
of the pro-domain of proNGF (the sortilin binding site) fused to
GST (Nykjaer et al., 2004) (Fig. 9A). When replicate layers of
CHO–mSort cells were incubated with conditioned media from
HEK293 cells secreting lipidated APOE2, APOE3, or APOE4,
avid internalization of all three human APOE isoforms was seen
by immunofluorescencemicroscopy. Little APOEuptakewas ob-
served in parental CHO cells lacking the receptor (Fig. 9B). Effi-
cient uptake of APOE in CHO–mSort but not in parental cells
was substantiated by Western blot analysis using recombinant
APOE4 lipidated with APOE-free HDL in vitro (Fig. 9C). Similar
findings were obtained with recombinant APOE2 and APOE3
(data not shown). To directly document the ability of sortilin to
act as a surface receptor for APOE, we immunostained CHO–
mSort cells incubated with the APO in the absence of detergent.
Colocalization of receptor and ligands at the cell surface of non-
permeabilized cells was readily visible for both APOE3 (Fig. 9D)
and APOE4 (Fig. 9E).
Sortilin mediates cellular uptake of A bound to APOE
Next, we confirmed the ability of sortilin to mediate cellular up-
take of A peptides when bound to APOE. Thus, we incubated
fluorescent-labeled A40 (HiLyte–A) with a 1:1 mixture of
APOE-free HDL and recombinant APOE3 or APOE4. This ratio
of APOE to HDL protein content is characteristic of lipoproteins
in the CSF (Koch et al., 2001). The APOE/A complexes were
applied in a final concentration of 5–10g of APOE permilliliter
to the culture medium. Similar concentrations of APOE have
beenmeasured in humanCSF (5g/ml) (Hesse et al., 2000). As a
negative control, HiLyte–A was mixed with APOE-free HDL
only. In line with our hypothesis, efficient uptake of A40 was
seen in cells expressing sortilin when the amyloid peptide was
complexed with lipidated APOE3 or APOE4 (CHO–mSort; Fig.
10A). In contrast, no sortilin-mediated uptake of HiLyte–Awas
seen in APOE-free HDL. Also, no uptake of free or APOE-bound
HiLyte–A40 was detectable in cells lacking receptor expression
(CHO; Fig. 10A). Sortilin-dependent uptake of A40 was also
confirmed using antiserum 4G8 (Fig. 10A, inset). Quantitative
analysis by ELISAdemonstrated an approximate fivefold increase
in uptake of APOE3-bound A40 in CHO–mSort compared with
parental CHOcells (Fig. 10B). Furthermore, threefold less uptake
was seen inCHO–mSort cells incubatedwith free A40 compared
with APOE3-bound A40, substantiating the ability of APOE to
promote sortilin-dependent clearance of the peptide (Fig. 10B).
Cellular uptake of APOE-bound A40 was reduced by the recep-
tor antagonists GST–pro and NT (Fig. 10C). Internalized A40
and APOE molecules colocalized with sortilin in intracellular
compartments of the cells (Fig. 11A). Colocalization of A40 with
themarker cathepsin B suggested predominant lysosomal target-
ing of the internalized peptides (Fig. 11B). To exclude any effect
of sortilin on cellular A40 production, we transiently transfected
replicate HEK293 cell layers with expression constructs for hu-
man APP and either mSort or empty control vector. Determina-
tion of A40 levels in cell supernatants after 48 h gave identical
results for parental HEK293 (121.7 13.62 pg A/ng APP; n
11) and HEK293–mSort cells (99.87 6.260 pg A/ng APP; n
11; p 0.39 by Mann–Whitney U test).
Sortilin is a major APOE receptor in neurons
A number of potential APOE receptors has been identified in
neurons and shown to affect turnover of APOE-bound A (for
review, see Holtzman et al., 2012). One receptor discussed in this
context is the low-density lipoprotein receptor-related protein 1
(LRP1), a member of the low-density lipoprotein (LDL) receptor
gene family (Liu et al., 2010). In addition, other receptors of this
gene family (including the LDL receptor itself) or VPS10P-
domain receptors, such as SORLA or SORCS1, SORCS2, and
SORCS3, may contribute to APO clearance in the brain. Com-
parative quantitative RT-PCR analysis revealed transcript levels
for Sort1 and Sorl1 (the gene encoding SORLA) in the murine
cortex that were 10- and 20-fold higher than those for Lrp1, ar-
Figure 4. Sortilin activity does not affect levels of A in plasma or levels of A peptide
degrading enzymes in the brain. A, Levels of A40 in plasma of PDAPP
/; Sort1/ and
PDAPP/; Sort1/ mice are given. Values are mean  SEM (n  4–5 per group). B,
Expression levels of CD10 (neprilysin) and insulin degrading enzyme (IDE) in hippocampus (Hip)
and cortex (Ctx) mice of the indicated genotypes were determined byWestern blotting. Detec-
tion of tubulin served as loading control.
362 • J. Neurosci., January 2, 2013 • 33(1):358–370 Carlo et al. • Sortilin Mediates APOE-Dependent Catabolism of A
guing for high levels of sortilin (and SORLA) expression in the
brain (Fig. 12A). Levels of transcripts encoding SORLA, LRP1,
LDL receptor, very-low-density lipoprotein receptor, LRP8, or
SORCS1, SORCS2, and SORCS3were unchanged in the cortex of
sortilin-deficient compared with wild-type mice as documented
by quantitative RT-PCR analyses (Fig. 12B). This finding argued
against reduced expression of any of these APOE receptors as the
underlying cause of APOE accumulation in sortilin null mice. In
support of this conclusion, no accumulation of APOEwas seen in
mice genetically deficient for Lrp1 or Sorl1 in this study. As shown
in the inset to Figure 12D, crossingmice carrying a loxP-modified
Lrp1 gene with animals expressing Cre recombinase under con-
trol of the neuron-specific enolase promoter (Nse–creCK1) re-
sulted in efficient elimination of receptor expression from the
brain. Still, levels of APOE in hippocampus and cortex of the
LRP1-deficent mice were not altered compared with matched
controls as shown by Western blotting (Fig. 12C) and by densi-
tometric scanning thereof (Fig. 12D). Also, mice carrying a tar-
geted disruption of Sorl1 (Andersen et al.,
2005) displayed similar levels of APOE in
cortex as wild-type controls (Fig. 12E,F).
To better appreciate the quantitative
importance of sortilin over other endo-
cytic receptors for neuronal catabolism of
A, we determined the uptake of APOE4-
bound A40 in primary neurons from
sortilin-deficient mice compared with
control mice. Despite normal expression
of LRP1 and SORLA in sortilin-deficient
neurons (Fig. 13A), these cells exhibited a
70–80% reduction in uptake of exoge-
nously added APOE/A40 complexes
compared with wild-type cells (Fig. 13B).
Similar to transfected HEK293 cells dis-
cussed above, the quantitative difference
in cellular handling of A was dependent
on the presence of APOE in the medium
as documented by testing the levels of en-
dogenous amyloidogenic products with-
out addition of APOE. Under these
experimental conditions, primary neu-
rons produce very low levels of the endog-
enous APO (Harris et al., 2004). In the
absence of exogenous APOE, the concen-
trations of sAPP and sAPP (Fig. 13C)
or of A40 and A42 (Fig. 13D) were not
changed in sortilin-deficient compared
with control neurons. Thus, sortilin activ-
ity does not impact the rate of A produc-
tion or clearance in neurons when APOE
is absent.
Lipid profiles in sortilin-deficient mice
recapitulate features of murine
APOE deficiency
So far, our data indicated a major role
for sortilin as APOE receptor in neu-
rons. To further substantiate this
model, we analyzed the brain lipid me-
tabolism in sortilin-deficient mice. One
of the main effects of altered APOE lev-
els in mice is a change in brain sulfatide
levels. Sulfatides are sulfated galactosyl-
ceramides synthesized by oligodendrocytes and incorporated
into the myelin sheath of axons. APOE-containing lipopro-
teins extract sulfatides from the myelin sheath and deliver
them to neurons for uptake and catabolism via APOE recep-
tors (Han et al., 2003; Cheng et al., 2010). Accordingly, loss of
APOE expression in Apoe/mice causes an approximate twofold
increase in brain sulfatide levels, whereas overexpression of human
APOE3andAPOE4reduces the concentrationof these lipids inmice
(Han et al., 2003). At 5 months of age, sortilin-deficient animals
exhibited a twofold increase in levels of the major brain sulfatide
variant N24:1 in the hippocampus. A significant increase in brain
sulfatides was also confirmed at 10 months of age (Fig. 14). In con-
trast to the situation with sortilin, deficiency for LRP1 did not affect
the brain levels of sulfatides inmice with conditional inactivation of
Lrp1 in neurons at 5months of age (Fig. 14). Because of the prema-
ture lethality ofmicewith brain-specific LRP1deficiency (May et al.,
2004), sulfatide levels could not be evaluated at later stages in this
line.
Figure 5. Histological analyses of sortilin-deficient mouse brains. Histological sections of the brain cortex from mice of the
indicated genotypes stained with thionine or with antisera directed against the neuronal marker NeuN or the glial marker GFAP.
Scale bars, 400m.
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In conclusion, our findings have identified a hitherto un-
known function for sortilin as neuronal APOE receptor in the
brain, and they uncovered APOE-dependent clearance as a mo-
lecular mechanism of receptor action in AD. Absence of this
receptor recapitulates features seen in mice lacking APOE (such
as accumulation of brain sulfatides) despite higher than normal
levels of the APO in the CNS. Because other neuronal APOE
receptors seemed properly expressed in sortilin-deficient mice,
our data suggest that sortilin represents a pathway ofmajor quan-
titative importance for neuronal clearance of APOE-containing
lipoproteins and APOE/A complexes.
Discussion
APOE is the most important genetic risk factor for sporadic AD
(Corder et al., 1993; Strittmatter et al., 1993). In the CNS, this 34
kDa protein is mainly produced by microglia and astrocytes (Pi-
tas et al., 1987) and delivers cholesterol-rich lipoproteins to neu-
rons to support synaptogenesis and maintenance of synaptic
connections (Mauch et al., 2001). Many hypotheses have been
advanced concerning the contribution of APOE to neurodegen-
eration, including effects on A clearance or deposition, on cell
signaling, neuroinflammation, synaptic transmission, or neuro-
toxicity (for review, see Mahley et al., 2006; Holtzman et al.,
2012). One common hypothesis states that APOE sequesters sol-
uble A in the extracellular space, resulting in cellular uptake and
catabolism of this neurotoxic peptide. This hypothesis is sup-
ported by many in vitro studies (Koistinaho et al., 2004;
Morikawa et al., 2005; Jiang et al., 2008). Data from transgenic
mouse models produced more conflicting results with impaired
plaque deposition seen inmice lackingmurineAPOE (Bales et al.,
1997; Holtzman et al., 2000) but also in animals overexpressing
the human APOE3 or APOE4 isoforms (Holtzman et al., 1999).
Still, recent findings that pharmacological induction of Apoe
expression in mice ameliorates A production and plaque depo-
sition strongly supports an inverse correlation of APOE concen-
tration with brain A levels (Cramer et al., 2012).
Although the multiple (and perhaps opposing) effects of
APOE on A degradation versus deposition still warrant clarifi-
cation, it is well appreciated that cellular APOE receptors likely
play critical roles in these processes. The two main receptors dis-
cussed in this context are the LDL receptor and LRP1. Whereas
the LDL receptormainlymediates uptake ofAPOE intomicroglia
and astrocytes (Kim et al., 2009), LRP1 constitutes an uptake
pathway for this APO in neurons (for review, see Holtzman et al.,
2012). Experimental support for involvement of LDL receptors
and LRP1 in brain APOE catabolism stems from the fact that
inactivation of either Ldlr or Lrp1 causes accumulation of APOE
in the brain of mice (Fryer et al., 2005; Liu et al., 2007). Con-
versely, overexpression of the LDL receptor (Kim et al., 2009) or
of LRP1 mini receptors reduces systemic levels of APOE in the
CNS (Zerbinatti et al., 2006). Now, our studies identified sortilin
as another APOE receptor to be considered in this context. Sorti-
lin binds and mediates cellular uptake of all human APOE iso-
forms (Figs. 9-11). Loss of receptor expression in gene-targeted
mice coincides with an increase in systemic APOE levels that
parallels increases seen in the LDL receptor null mice (100% in
Sort1/ vs 60% in Ldlr/ lines) (Fig. 6A,B) (Fryer et al., 2005).
The rate of Apoe transcription (Fig. 6C) or of APOE release from
astrocytes (Fig. 7) is unchanged in sortilin-deficient animals, sug-
gesting impaired clearance as the cause of APOE buildup. Most
importantly, sortilin mediates cellular uptake of A bound to
APOE (Fig. 10) and receptor deficiency results in accumulation
of A peptides and in increased plaque burden in two ADmouse
models (Figs. 1, 3). In contrast to A, the levels of other soluble or
membrane-tethered APP processing products are not affected by
receptor deficiency (Figs. 1, 2, 13C). Although our data substan-
tiate an important role for sortilin in amyloidogenic processes,
they disagree with previous studies in cellular overexpression sys-
tems that argued for a direct role of this receptor in APP process-
ing through regulation of -secretase trafficking (Finan et al.,
2011).
Recently, sortilin was identified as a genetic risk factor in car-
diovascular disease associated with high plasma cholesterol levels
and occurrence of myocardial infarction in the human popula-
tion (Kathiresan et al., 2009). The underlying mechanism was
traced to the ability of sortilin to act as intracellular sorting recep-
tor for APOB100 and to modulate release of nascent APOB100-
containing lipoproteins from the liver (Kjolby et al., 2010;
Musunuru et al., 2010). Intriguingly, our studies now uncovered
the relevance of this receptor pathway in control of lipoprotein
homeostasis in the brain as well. Support for a critical role for
sortilin in systemic APOE metabolism stems from changes in
lipid profiles in sortilin-deficient mice that recapitulate features
Figure6. Accumulation of APOE in thebrain of sortilin-deficientmice.A,B, Levels of APOE in
hippocampus (Hip) and cortex (Ctx) of wild-type (Sort1/) and sortilin-deficient (Sort1/)
mice at 3 months of age were determined by Western blot analyses (A) and quantified by
densitometric scanning of the respective membranes (n 6 per group) (B). In A, detection of
tubulin served as loading control. Extracts frommice genetically deficient for APOE (Apoe/)
were used as negative control for specificity of the APOE immunoreactivity (indicated by arrow-
heads). A similar difference in APOE levels was also seen inmice at 9months of age (Sort1/,
100.0 10.19%, n 6; Sort1/, 176.1 10.3%, n 7). C, Quantitative RT-PCR analyses
of Apoe mRNA levels in hippocampus and cortex of Sort1/ and Sort1/ animals at 2
months of age (n4per group). All values aremean SEMandaregivenas percentageof the
wild-type control (mean set at 100%). Significant differences between genotypes are indicated
(**p 0.01, ***p 0.001).
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shown for Apoe/ animals previously
(Han et al., 2003). Thus, although total
levels of cholesterol remain unaltered
(data not shown), loss of sortilin coincides
with elevated hippocampal levels of sul-
fatides that are in the same order of mag-
nitude as in APOE-deficient animals
(twofold) (Fig. 14) (Han et al., 2003). Al-
though the molecular pathways involved
in APOE-dependent turnover of brain
sulfatides are poorly understood, levels of
the APO are typically inversely correlated
with levels of these lipids (Han et al.,
2003). Sortilin-deficient animals exhibit
elevated sulfatide concentrations albeit at
higher than normal levels of APOE. These
data strongly argue for a defect in neuro-
nal clearance of APOE-containing lipo-
proteins (and associated sulfatides) in
mice lacking this receptor.
In the brain, endocytic pathways in glia
cells (likely the LDL receptor) and in neu-
rons are implicated in cellular catabolism
ofAPOE/A complexes (Koistinaho et al.,
2004; Jiang et al., 2008; Holtzman et al.,
2012). Because expression of sortilin in
the CNS is restricted to neurons (Sarret et
al., 2003), we assessed the quantitative
contribution of this receptor pathway to
neuronal APOE/A catabolism. Surpris-
ingly, APOE-dependent uptake of Awas
impaired in primary neurons lacking
sortilin despite normal levels of LRP1 and
SORLA (Fig. 13). Also, transcript levels
of members of the LDL receptor and
VPS10P-domain receptor gene families
were not affected by sortilin deficiency
(Fig. 12B), strongly arguing for a direct
effect of sortilin on APOE and A turn-
over in vivo. In support of our model, no
accumulation of APOE was seen in mice
lacking SORLA or LRP1 in this study (Fig.
12C–F). In addition, accumulation of
brain sulfatides was seen in sortilin-
deficient but not in LRP1-deficient ani-
mals in this study (Fig. 14). In line with
this notion, lower (rather than higher)
sulfatide levels were observed in another
mouse model with neuron-specific LRP1
deficiency previously (Liu et al., 2010). Fi-
nally, neuron-specific inactivation of Lrp1
was shown to decrease brain A levels
(Liu et al., 2007), whereas overexpression
of an LRP1 mini receptor was shown to
increase brain A levels (Zerbinatti et al.,
2006). Obviously, many of these data are
inconsistentwith a simple role for LRP1 in
neuronal APOE/A clearance. Likely, the
multiple alternative functions assigned to
this receptor in AD, including intracellu-
lar APP transport (Ulery et al., 2000; Pi-
etrzik et al., 2002), blockade of APP
signaling (Kinoshita et al., 2003), or A
Figure 7. Sortilin activity does not impact APOE release from primary astrocytes. APOE was immunoprecipitated from
cell lysate and conditionedmedia of primary cultures of astrocytes of newborn Sort1/ and Sort1/ animals. The levels
of APOE in lysate and media at the indicated time points were determined by autoradiography (A) and quantified by
densitometric scanning of replicate blots (B). APOE levels were normalized with respect to the sample with the highest
level of APOE in lysate or media (set at 100%), respectively. Bar graphs in B show mean SD value of three separate
experiments.
Figure 8. Sortilin interacts with all human APOE isoforms. A–C, Surface plasmon resonance analyses of ligand binding
to sortilin immobilized on the BIAcore chip surface. Binding of APOE-free liposomes and of liposomes complexed with
recombinant APOE2 (A), APOE3 (B), and APOE4 (C) was tested in the presence and absence of 20M NT. D, Surface plasmon
resonance analyses of binding of a concentration series of A40 to sortilin immobilized on the BIAcore chip surface.
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shunt across the blood–brain barrier (Deane et al., 2004) com-
plicate interpretation of the available experimental data.
All evidence in this study is consistent with a model whereby
sortilin represents amajor neuronal receptor pathway for APOE-
containing lipoproteins that counteracts A accumulation in the
brain. Sortilin-mediated endocytosis likely results in lysosomal
degradation of the A peptides (Fig. 11B). A related role for
sortilin as neuronal clearance receptor has been shown recently
for progranulin, a protein implicated in frontotemporal lobar
degeneration (Hu et al., 2010). In this study, we observed low-
affinity binding of A to sortilin in BIAcore (Fig. 8) and some
residual uptake of the free peptide in CHO–mSort cells (Fig.
10A,B). Thus, we cannot exclude that sortilin may also clear free
A in vivo. However, one has to keep in mind that the concen-
tration of A applied to cells (0.7 g/ml) is significantly higher
than the amount of total A detected, for example, in the
PDAPP/ mouse brain (3 ng/ml) (Castellano et al., 2012).
Also, Deane et al. (2004) documented an affinity for A binding
to LRP1 (Kd  0.57 nM) that is a 1000-fold higher than the one
determined for sortilin. Data obtained so far also failed to identify
obvious differences in cellular handling of APOE3 versus APOE4
by sortilin. However, we noticed a twofold lower Kd for binding
of APOE3 (44 nM) versus APOE4 (114 nM) (Fig. 8). Also, NT
blocked receptor interaction with APOE3 much more efficiently
than with APOE4 (80 vs 30% inhibition, respectively) (Fig. 8).
These observations point toward an isoform-specific interaction
Figure 9. Sortilin mediates cellular uptake of human APOE. A, B, Replicate layers of parental CHO cells or CHO cells overexpressing murine sortilin (CHO–mSort) were incubated with blank
medium (mock), withmedium containing 500 nM of the pro-domain of NGF fused to GST (GST–pro), or with conditionedmedia fromHEK293 cells transfectedwith expression constructs for human
APOE2, APOE3, or APOE4. Receptor-dependent uptake of ligands was determined by immunodetection of sortilin (A), GST–pro (A), as well as APOE (B). Arrowheads highlight the localization of
receptor and ligands in theperinuclear region of the cells. The inset inA indicates lack of liganduptake in cells treatedwithGST insteadof GST–pro. Scale bars, 4m.C, Detection of APOE and tubulin
(loading control) in extracts of parental CHO or CHO–mSort cells incubated for 30 min with lipidated recombinant APOE4. When indicated, the medium also contained 10M NT or GST–Pro (pro).
D, E, Detection of sortilin and APOE3 (D) and sortilin and APOE4 (E) on the surface of nonpermeabilized CHO–mSort cells by immunocytochemistry. Insets inD and E show themerged pictures, with
white color indicating colocalization of sortilin (blue) and APOE (green) on the cell surface. Scale bars, 4m.
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of sortilin with human APOE. Whether this distinction may ex-
plain differences in risk of AD associated with these two APOE
variants remains to be resolved. Regardless of possible differences
in handling of APOE3 versus APOE4, the ability of sortilin to
modulate brain lipid and APOE homeostasis strongly implicates
this receptor pathway in pathophysiological mechanisms
whereby alterations in brain lipoprotein metabolism affect the
risk of sporadic AD.
In conclusion, our studies have identified the pro-neurotrophin
receptor sortilin as a major neuronal pathway involved in brain
APOEandAmetabolism.Thus, this receptor represents a pathway
in which pro-neurotrophin signaling, A catabolism, and brain li-
poproteinmetabolism converge. Additional studies are likely to un-
cover exciting details of this protein critical to several important
concepts in neurodegeneration.
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